|

Topoisomerase-1 Inhibitor LMP744 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: 308246-52-8, 5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-Hydroxyethyl)amino)propyl)-2,3-dimethoxy-, Indenoisoquinoline, LMP-744, LMP744

Pipeline

Early 1: 1

Top Sponsors

  • Mayo Clinic1

Indications

Rochester, Minnesota1 trial

Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

Mayo Clinic in Rochester

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.